Spero Therapeutics Inc (SPRO)

$0.75 +0.01 (1.92%)
Market Cap 42.16M
Revenue (ttm) 47.98M
Net Income (ttm) -68.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -142.91%
Debt to Equity Ratio 0.00
Volume 35,900
Avg Vol 142,096
Day's Range N/A - N/A
Shares Out 55.90M
Stochastic %K 77%
Beta 0.64
Analysts Sell
Price Target $5.00

Latest News on SPRO

Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:31 PM EDT - 23 days ago

Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Mar 27, 2025, 4:01 PM EDT - 23 days ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

Mar 18, 2025, 8:00 AM EDT - 4 weeks ago

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 10:15 AM EST - 7 weeks ago

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 7 weeks ago

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal

Jan 19, 2025, 8:00 AM EST - 3 months ago

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Jan 10, 2025, 7:00 AM EST - 3 months ago

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Nov 14, 2024, 4:05 PM EST - 5 months ago

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Oct 16, 2024, 4:05 PM EDT - 6 months ago

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Oct 2, 2024, 4:30 PM EDT - 7 months ago

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 10:47 AM EDT - 9 months ago

Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

Aug 5, 2024, 4:01 PM EDT - 9 months ago

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

Jul 29, 2024, 4:05 PM EDT - 9 months ago

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2024, 1:05 PM EDT - 10 months ago

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

May 16, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

May 15, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

May 8, 2024, 8:00 AM EDT - 1 year ago

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2024, 4:07 PM EDT - 1 year ago

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23, 2024, 11:37 AM EDT - 1 year ago

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 5:45 PM EDT - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Mar 13, 2024, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Mar 6, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Feb 28, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

Feb 26, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Jan 5, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Jan 2, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:05 PM EST - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 6, 2023, 8:05 AM EST - 1 year ago

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Nov 1, 2023, 8:05 AM EDT - 1 year ago

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

Sep 20, 2023, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:05 AM EDT - 1 year ago

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Aug 3, 2023, 8:05 AM EDT - 1 year ago

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Jul 31, 2023, 8:05 AM EDT - 1 year ago

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK

Jul 5, 2023, 3:06 PM EDT - 1 year ago

Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

Jun 14, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

Spero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Call Transcript

May 11, 2023, 8:59 PM EDT - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Call Transcript

Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update

May 11, 2023, 4:05 PM EDT - 2 years ago

Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update

Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

May 4, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Spero Therapeutics to Present at Upcoming Investor Conference

Apr 26, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Present at Upcoming Investor Conference

Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market

Apr 21, 2023, 4:46 PM EDT - 2 years ago

Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market

Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Apr 14, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Spero Therapeutics, Inc. (SPRO) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 10:11 PM EDT - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q4 2022 Earnings Call Transcript

Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update

Mar 30, 2023, 4:05 PM EDT - 2 years ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update

Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023

Mar 13, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023

Mar 6, 2023, 8:05 AM EST - 2 years ago

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023

Spero Therapeutics to Present at Upcoming Investor Conferences

Feb 28, 2023, 8:05 AM EST - 2 years ago

Spero Therapeutics to Present at Upcoming Investor Conferences

Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

Nov 22, 2022, 8:05 AM EST - 2 years ago

Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

Spero Therapeutics, Inc. (SPRO) Q3 2022 Earnings Call Transcript

Nov 14, 2022, 10:14 PM EST - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q3 2022 Earnings Call Transcript